|Bid||275.00 x 800|
|Ask||330.72 x 900|
|Day's Range||329.82 - 339.08|
|52 Week Range||159.01 - 387.40|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||75.34|
|Earnings Date||Apr 29, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||378.00|
Abiomed's (NASDAQ:ABMD) stock is up by a considerable 9.4% over the past month. Given the company's impressive...
Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for Impella in high-risk percutaneous coronary intervention (HRPCI). The first patient was enrolled at Ascension St. John Hospital in Detroit by Dr. Ted Schreiber, chief of cardiology at Ascension St. John Macomb-Oakland Hospital and Dr. Amir Kaki, interventional cardiologist and director of mechanical circulatory support at Ascension St. John Hospital.
Here, I'll talk about three overlooked healthcare stocks to buy now for big reward potential well into the future. Intuitive Surgical (NASDAQ: ISRG) has slipped about 6% since the start of the year. This leader in robotic surgery holds more than 80% of the global market, a report from Informa Pharma Intelligence shows.